Skip to main content
    A

    Axsome Therapeutics Inc (AXSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $141.69
    -2.68 (-1.86%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Axsome Therapeutics Inc (AXSM) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Axsome Therapeutics (AXSM) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Axsome Therapeutics reported EPS of -$0.25, above the -$0.69 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/40)
    Avg Surprise
    -6.20%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.01
    Range-$0.53 - $0.67
    24 analysts
    Revenue Consensus
    $291.88M
    Range$254.50M - $343.35M
    23 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.03
    Range-$0.21 - $0.27
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.30-89.9%
    60d ago$0.12-74.2%
    30d ago$0.16-81.7%
    7d ago-$0.34+108.8%
    Current$0.03
    Revenue Consensus
    $297.49M
    Range$277.20M - $335.47M
    7 analysts

    Next Report

    AXSM has an expected report date of Feb 10, 2027.

    AXSM Earnings Call

    The latest AXSM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AXSM beat 15, missed 22 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $259.69M, up 51.9% from $170.99M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$0.69-$1.00 - -$0.41+63.77%BeatN/A130 up, 3 downNov 2, 2026$259.69M
    Jun 30, 2026-$0.99-$0.99-$1.25 - -$0.050.00%In lineN/A111 up, 0 downAug 10, 2026$218.38M
    Mar 31, 2026-$1.26-$0.86-$1.05 - -$0.21-46.51%MissN/A61 up, 2 downMay 4, 2026$191.20M
    Dec 31, 2025-$0.56-$0.73-$1.16 - -$0.28+22.82%BeatN/A154 up, 1 downFeb 23, 2026$196.00M
    Sep 30, 2025-$0.94-$0.90-$1.19 - -$0.57-4.44%MissN/A141 up, 3 downNov 3, 2025$170.99M
    Jun 30, 2025-$0.97-$1.09-$1.24 - -$0.75+11.01%BeatN/A130 up, 6 downAug 4, 2025$150.04M
    Mar 31, 2025-$1.22-$1.35-$1.69 - -$0.81+9.63%BeatN/A101 up, 3 downMay 5, 2025$121.46M
    Dec 31, 2024-$1.54-$1.00-$1.32 - -$0.55-53.60%MissN/A116 up, 2 downFeb 18, 2025$118.77M
    Sep 30, 2024-$1.34-$1.41-$1.70 - -$0.78+4.83%BeatN/A163 up, 0 downNov 12, 2024$104.76M
    Jun 30, 2024-$1.67-$1.33-$1.67 - -$0.97-25.56%MissN/A162 up, 0 downAug 5, 2024$87.17M
    Mar 31, 2024-$1.44-$1.22-$1.45 - -$0.98-18.03%MissN/A152 up, 1 downMay 6, 2024$75.00M
    Dec 31, 2023-$2.08-$1.17-$1.36 - -$1.07-77.78%MissN/A142 up, 1 downFeb 20, 2024$71.53M
    Sep 30, 2023-$1.32-$1.19-$1.33 - -$0.93-10.92%MissN/A112 up, 0 downNov 6, 2023$57.79M
    Jun 30, 2023-$1.54-$1.20-$1.48 - -$0.97-28.33%MissN/A116 up, 0 downAug 7, 2023$46.70M
    Mar 31, 2023-$0.26-$1.04-$1.50 - $0.34+75.00%BeatN/A122 up, 0 downMay 8, 2023$94.58M
    Dec 31, 2022-$1.41-$1.14-$1.59 - -$0.72-23.68%MissN/A151 up, 0 downFeb 27, 2023$24.37M
    Sep 30, 2022-$1.07-$1.10-$1.63 - -$0.84+2.73%BeatN/A142 up, 0 downNov 7, 2022$16.85M
    Jun 30, 2022-$1.06-$1.12-$2.28 - -$0.84+5.36%BeatN/A122 up, 0 downAug 9, 2022$8.82M
    Mar 31, 2022-$1.03-$1.01-$1.35 - -$0.83-1.98%MissN/A111 up, 1 downMay 2, 2022N/A
    Dec 31, 2021-$0.90-$1.02-$1.46 - -$0.91+11.76%BeatN/A120 up, 0 downMar 1, 2022N/A
    Sep 30, 2021-$0.93-$0.93-$1.22 - -$0.830.00%In lineN/A13N/ANov 8, 2021N/A
    Jun 30, 2021-$0.86-$0.88-$1.56 - -$0.76+2.27%BeatN/A14N/AAug 9, 2021N/A
    Mar 31, 2021-$0.78-$0.81-$1.49 - -$0.63+3.70%BeatN/A14N/AMay 10, 2021N/A
    Dec 31, 2020-$0.78-$0.76-$1.52 - -$0.57-2.63%MissN/A14N/AMar 1, 2021N/A
    Sep 30, 2020-$0.58-$0.55-$0.76 - -$0.45-5.45%MissN/A11N/ANov 5, 2020N/A
    Jun 30, 2020-$0.49-$0.61-$0.87 - -$0.48+19.67%BeatN/A9N/AAug 10, 2020N/A
    Mar 31, 2020-$0.88-$0.62-$0.69 - -$0.51-41.94%MissN/A9N/AMay 8, 2020N/A
    Dec 31, 2019-$0.71-$0.46-$0.63 - -$0.35-54.35%MissN/A8N/AMar 12, 2020N/A
    Sep 30, 2019-$0.56-$0.39-$0.46 - -$0.35-43.59%MissN/A8N/ANov 7, 2019N/A
    Jun 30, 2019-$0.41-$0.31-$0.33 - -$0.28-32.26%MissN/A6N/AAug 8, 2019N/A
    Mar 31, 2019-$0.32-$0.30-$0.35 - -$0.27-6.67%MissN/A5N/AMay 9, 2019N/A
    Dec 31, 2018-$0.32-$0.30-$0.33 - -$0.26-6.67%MissN/A4N/AMar 14, 2019N/A
    Sep 30, 2018-$0.31-$0.28N/A-10.71%MissN/AN/AN/ANov 9, 2018N/A
    Jun 30, 2018-$0.32-$0.27-$0.32 - -$0.27-18.52%MissN/A2N/AAug 8, 2018N/A
    Mar 31, 2018-$0.29-$0.28-$0.28 - -$0.28-3.57%MissN/A2N/AMay 8, 2018N/A
    Dec 31, 2017-$0.31-$0.31N/A0.00%In lineN/A1N/AMar 7, 2018N/A
    Sep 30, 2017-$0.27-$0.34N/A+20.59%BeatN/AN/AN/ANov 8, 2017N/A
    Jun 30, 2017-$0.30-$0.34N/A+11.76%BeatN/AN/AN/AAug 9, 2017N/A
    Mar 31, 2017-$0.41-$0.39N/A-5.13%MissN/AN/AN/AMay 9, 2017N/A
    Dec 31, 2016-$0.38-$0.42N/A+9.52%BeatN/AN/AN/AMar 7, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.69, after -$5.99 the year before. It was -$1.43 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.69N/A
    Dec 31, 2024-$5.99N/A
    Dec 31, 2023-$5.20N/A
    Dec 31, 2022-$4.57N/A
    Dec 31, 2021-$3.47N/A
    Dec 31, 2020-$2.73N/A
    Dec 31, 2019-$2.00N/A
    Dec 31, 2018-$1.24N/A
    Dec 31, 2017-$1.29N/A
    Dec 31, 2016-$1.43N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 28 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,89228
    2026Q2Jun 30, 20266,52225
    2026Q1Mar 31, 20267,83723
    2025Q4Dec 31, 20257,09224
    2025Q3Sep 30, 20256,50325
    2025Q2Jun 30, 20256,29724
    2025Q1Mar 31, 20256,98925
    2024Q4Dec 31, 20246,44222

    2026Q3 Earnings Call

    Opening remarks

    Ashley Dong Senior Director of Investor Relations Thank you. Good morning, everyone. Welcome to Axsome's Third Quarter 2026 Earnings Conference Call. Joining me today are Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; and Ari Maizel, Chief Commercial Officer. We will begin with prepared remarks. Mark L. Jacobson, our Chief Operating Officer, and Hunter Murdock, our General Counsel, will also be available for Q&A. Before we begin, I encourage everyone to visit the Investors section of our website to find the press release and presentation for today's call. Please note that today's discussion includes forward-looking statements regarding our financial performance, commercial strategy, and operational plans, including research, development, and regulatory activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our SEC filings, including our quarterly and annual reports, for a description of these and other risks. You are cautioned not to rely on these forward-looking statements, which are made only as of today, and the company disclaims any obligation to update such statements. With that, I will hand it over to Ari.

    Herriot Tabuteau Chief Executive Officer Thank you, Ashley, and good morning, everyone. Axsome delivered another robust quarter across our business, driven by continued commercial progress and advancements in our industry-leading neuroscience pipeline. Our commercial portfolio generated $260 million in total revenue in the quarter, representing growth of 52% year-over-year and surpassing a $1 billion annual run rate. We expect sustained momentum for AUVELITY, driven by strong underlying demand growth in major depressive disorder and continued acceleration of new patients in Alzheimer's disease agitation. SUNOSI continues to show persistent and steady growth. For SYMBRAVO, our expanded sales team is driving important trial and adoption. Nick will discuss our financials for the quarter, followed by Ari, who will comment on our commercial business. In parallel with the commercial portfolio, our industry-leading neuroscience pipeline comprises 10 development programs, including significant label expansion opportunities for AUVELITY and SUNOSI, as well as novel product candidates with potential first-in-class and best-in-class profiles across areas of high unmet need in brain health. I will review our recent pipeline progress later in the call. Overall, our commercial portfolio is growing, and our industry-leading R&D portfolio is well positioned to potentially deliver multiple waves of innovation to patients. I will now turn the call over to Nick to review our financials.

    Nick Pizzie Chief Financial Officer Thanks, Herriot, and good morning, everyone. Total revenue reached $260 million in the third quarter, representing accelerated growth of 52% year-over-year and 19% sequentially. AUVELITY net product sales were $208 million, representing 53% year-over-year growth and an increase of over 15% sequentially.

    Frequently Asked Questions About AXSM

    When is Axsome Therapeutics's next earnings date?

    Axsome Therapeutics's next earnings report is expected for Feb 10, 2027.

    Did AXSM beat earnings estimates last quarter?

    Yes. Axsome Therapeutics reported EPS of -$0.25 for the quarter ended Sep 30, 2026, above the -$0.69 estimate, a 63.77% surprise.

    What EPS do analysts expect from AXSM next quarter?

    The consensus EPS estimate for Axsome Therapeutics for the quarter ending Dec 31, 2026 is -$0.01 from 24 analysts, with estimates from -$0.53 to $0.67.

    How often does AXSM beat earnings estimates?

    Axsome Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +0.33%.